Frontiers in Clinical Drug Research – Anti Allergy Agents

Volume: 1

Indexed in: EBSCO, Scopus.

Frontiers in Clinical Drug Research - Anti-Allergy Agents is an exciting eBook series comprising a selection of updated review articles relevant to the recent development of pharmacological agents ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Omalizumab Therapy for Allergic Diseases

Pp. 118-161 (44)

Juan Antonio Martinez-Tadeo, Eva Perez-Rodriguez and Zulay Almeida-Sanchez


The antibody omalizumab is a humanized anti-IgE monoclonal binding to IgE circulating preventing binding to receptors and thereby inhibiting the cascade of allergic inflammation. Besides achieving a reduction in expression of IgE receptors on the surface of basophils and expression of high affinity receptor for IgE on the surface of dendritic cells. Its use has been approved for patients aged 6 years old with moderate to severe allergic asthma, also has been effective in other diseases such as asthma of occupational origin, seasonal or perennial allergic rhinitis, chronic urticaria difficult to control and helping to better tolerance immunotherapy. The results obtained in different studies on treatment with omalizumab in severe atopic dermatitis are contradictory. While providing a promising effect in the treatment of food and drug allergy more longterm studies are needed.


Omalizumab, asthma, IgE, antiIgE, food allergy, drug allergy, atopic dermatitis, chronic urticaria, immunotherapy, mastocytosis.


Allergy and Immunology Service, Hospital Universitario Ntra. Sra. De Candelaria, Spain.